Register for citation alerts

Implantable port associated doxorubicin extravasation

"Catheter misplacement should be suspected in any patient presenting with post procedural chest pain and should trigger a thorough evaluation prior to any chemotherapy administration" Kazakova et al (2020).

Abstract:

Introduction: Intrathoracic extravasation of anthracyclines is a dangerous and very rare complication of chemotherapy administration. While management of extravasation into soft tissues has been established, the data on treatment of mediastinal and intrapleural anthracycline extravasation is limited.

Case report: We present a case of a 52-year-old woman with intrapleural doxorubicin extravasation who presented to the hospital 24-hrs after chemotherapy infusion with chest pain and shortness of breath.

Management & outcome: The patient underwent urgent surgical intervention and received IV dexrazoxane 36-hrs after the event. Her pain improved, but she continued to have chest soreness and pleural effusion at the site of extravasation even 3 months later.

Discussion: We conducted review of literature using Medline/PubMed and Google Scholar databases and identified 7 cases of intrapleural and mediastinal anthracycline extravasation. No data is currently available regarding the outcome of delayed management of intrapleural anthracycline extravasation with dexrazoxane. Prevention and confirmation of adequate port catheter placement is the most important step to avoid such cases. Catheter misplacement should be suspected in any patient presenting with post procedural chest pain and should trigger a thorough evaluation prior to any chemotherapy administration.

Reference:

Kazakova V, Vanegas YAM, Torres TA, Kozyreva O. Delayed presentation of doxorubicin extravasation into pleural space: Case report and review of literature. J Oncol Pharm Pract. 2020 Nov 26:1078155220975848. doi: 10.1177/1078155220975848. Epub ahead of print. PMID: 33241731.